HealthDay News — For older men with at least 1 cardiovascular risk factor, treatment with statin and/or pharmacologic blood pressure reduction does not significantly impact erectile function, according to a study published in the January issue of the Canadian Journal of Cardiology.
Philip Joseph, MD, from McMaster University in Hamilton, Canada, and colleagues conducted a secondary analysis of the Heart Outcomes Prevention Evaluation-3 randomized controlled trial involving 2,153 men age 55 years or older with 1 or more cardiovascular risk factors. Participants were randomized to rosuvastatin or placebo and to candesartan with hydrochlorothiazide (Cand+HCTZ) or placebo in a 2 × 2 factorial design.
The researchers found that at baseline, the mean erectile function domain of the International Index of Erectile Function (IIEF-EF) score was 23.0. No significant differences were seen in the least square mean change in the IIEF-EF score with rosuvastatin versus placebo (−1.4 versus −1.5; P=0.74), Cand+HCTZ versus placebo (−1.6 versus −1.3; P=0.10) or combination therapy versus double placebo (P=0.35).
“Cholesterol-lowering using a statin, and blood pressure-lowering using Cand+HCTZ, either alone or in combination, do not improve or adversely affect erectile function,” the authors write.
Several authors disclosed financial ties to AstraZeneca.